

Guido Poli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1072686/publications.pdf>

Version: 2024-02-01

198
papers

8,131
citations

38742

50
h-index

58581

82
g-index

202
all docs

202
docs citations

202
times ranked

9512
citing authors

#	ARTICLE	IF	CITATIONS
1	Towards an HIV cure: a global scientific strategy. <i>Nature Reviews Immunology</i> , 2012, 12, 607-614.	22.7	485
2	The Effect of Cytokines and Pharmacologic Agents on Chronic HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 1992, 8, 191-197.	1.1	247
3	Macrophage Polarization in Health and Disease. <i>Scientific World Journal, The</i> , 2011, 11, 2391-2402.	2.1	237
4	Interleukin 10 Increases CCR5 Expression and HIV Infection in Human Monocytes. <i>Journal of Experimental Medicine</i> , 1998, 187, 439-444.	8.5	230
5	Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. <i>Aids</i> , 1998, 12, 1327-1332.	2.2	226
6	Interleukin-6 Induces Monocyte Chemotactic Protein-1 in Peripheral Blood Mononuclear Cells and in the U937 Cell Line. <i>Blood</i> , 1998, 91, 258-265.	1.4	205
7	Persistent Microbial Translocation and Immune Activation in HIV-1 Infected South Africans Receiving Combination Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2010, 202, 723-733.	4.0	178
8	M1 and M2a Polarization of Human Monocyte-Derived Macrophages Inhibits HIV-1 Replication by Distinct Mechanisms. <i>Journal of Immunology</i> , 2009, 182, 6237-6246.	0.8	172
9	Biological and Technical Variables Affecting Immunoassay Recovery of Cytokines from Human Serum and Simulated Vaginal Fluid: A Multicenter Study. <i>Analytical Chemistry</i> , 2008, 80, 4741-4751.	6.5	161
10	Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14658-14663.	7.1	154
11	Interleukin 10 Blocks HIV Replication in Macrophages by Inhibiting the Autocrine Loop of Tumor Necrosis Factor α and Interleukin 6 Induction of Virus. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 1199-1206.	1.1	151
12	Interferon gamma induces the expression of human immunodeficiency virus in persistently infected promonocytic cells (U1) and redirects the production of virions to intracytoplasmic vacuoles in phorbol myristate acetate-differentiated U1 cells.. <i>Journal of Experimental Medicine</i> , 1992, 176, 739-750.	8.5	148
13	Cytokine modulation of HIV expression. <i>Seminars in Immunology</i> , 1993, 5, 165-173.	5.6	146
14	Macrophage polarization and HIV-1 infection. <i>Journal of Leukocyte Biology</i> , 2009, 87, 599-608.	3.3	139
15	Monocyte-derived macrophages and myeloid cell lines as targets of HIV-1 replication and persistence. <i>Journal of Leukocyte Biology</i> , 2006, 80, 1018-1030.	3.3	133
16	<i>Coronaviridae</i> and SARS-associated Coronavirus Strain HSR1. <i>Emerging Infectious Diseases</i> , 2004, 10, 413-418.	4.3	127
17	Activated B lymphocytes from human immunodeficiency virus-infected individuals induce virus expression in infected T cells and a promonocytic cell line, U1.. <i>Journal of Experimental Medicine</i> , 1991, 173, 1-5.	8.5	126
18	Human CD34+ Cells Express CXCR4 and Its Ligand Stromal Cell-Derived Factor-1. Implications for Infection by T-Cell Tropic Human Immunodeficiency Virus. <i>Blood</i> , 1999, 94, 62-73.	1.4	117

#	ARTICLE	IF	CITATIONS
19	Cloning and characterization of a new isoform of the interleukin 1 receptor antagonist.. Journal of Experimental Medicine, 1995, 182, 623-628.	8.5	112
20	Association Study of Common Genetic Variants and HIV-1 Acquisition in 6,300 Infected Cases and 7,200 Controls. PLoS Pathogens, 2013, 9, e1003515.	4.7	109
21	Role of cytokines and chemokines in the regulation of innate immunity and HIV infection. Molecular Immunology, 2005, 42, 161-182.	2.2	106
22	Selective Elevation of Monocyte Chemotactic Protein-1 in the Cerebrospinal Fluid of AIDS Patients with Cytomegalovirus Encephalitis. Journal of Infectious Diseases, 1996, 174, 1098-1100.	4.0	101
23	A family of serine proteases expressed exclusively in myelo-monocytic cells specifically processes the nuclear factor-kappa B subunit p65 in vitro and may impair human immunodeficiency virus replication in these cells.. Journal of Experimental Medicine, 1994, 180, 1445-1456.	8.5	99
24	Human Immunodeficiency Virus Replication Induces Monocyte Chemotactic Protein-1 in Human Macrophages and U937 Promonocytic Cells. Blood, 1999, 93, 1851-1857.	1.4	92
25	Retinoic acid mimics transforming growth factor beta in the regulation of human immunodeficiency virus expression in monocytic cells.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 2689-2693.	7.1	87
26	TRIM22 Inhibits HIV-1 Transcription Independently of Its E3 Ubiquitin Ligase Activity, Tat, and NF- κ B-Responsive Long Terminal Repeat Elements. Journal of Virology, 2011, 85, 5183-5196.	3.4	87
27	Inhibition of CXCR4-Dependent HIV-1 Infection by Extracellular HIV-1 Tat. Biochemical and Biophysical Research Communications, 2000, 270, 992-996.	2.1	83
28	HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells. Nature Communications, 2017, 8, 498.	12.8	78
29	Constitutive Activation of STATs Upon In Vivo Human Immunodeficiency Virus Infection. Blood, 1999, 94, 4202-4209.	1.4	77
30	Increased Sensitivity of Sars-Coronavirus to a Combination of Human Type I and Type II Interferons. Antiviral Therapy, 2004, 9, 1003-1011.	1.0	77
31	Interferons in the pathogenesis and treatment of human immunodeficiency virus infection. Antiviral Research, 1994, 24, 221-233.	4.1	73
32	NF- κ B-Dependent and -Independent Pathways of HIV Activation in a Chronically Infected T Cell Line. Virology, 1994, 202, 684-694.	2.4	72
33	Productive HIV-1 infection of human cervical tissue ex vivo is associated with the secretory phase of the menstrual cycle. Mucosal Immunology, 2013, 6, 1081-1090.	6.0	71
34	The Role of Monocyte/Macrophages and Cytokines in the Pathogenesis of HIV Infection. Pathobiology, 1992, 60, 246-251.	3.8	70
35	Shorter Survival of SDF1 β Homozygotes Linked to CD4+T Cell Decrease in Advanced Human Immunodeficiency Virus Type 1 Infection. Journal of Infectious Diseases, 2000, 182, 311-315.	4.0	70
36	Role of proinflammatory cytokines and β -chemokines in controlling HIV replication. Journal of Leukocyte Biology, 1997, 62, 34-40.	3.3	67

#	ARTICLE	IF	CITATIONS
37	A General Strategy to Endow Natural Fusion-protein-Derived Peptides with Potent Antiviral Activity. PLoS ONE, 2012, 7, e36833.	2.5	67
38	Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. Blood, 2006, 107, 4825-4833.	1.4	66
39	Upregulated expression of interleukin-8, RANTES and chemokine receptors in human astrocytic cells infected with HIV-1. Journal of NeuroVirology, 2000, 6, 75-83.	2.1	64
40	CCR2 Polymorphism and HIV Disease. Nature Medicine, 1998, 4, 252-253.	30.7	63
41	Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8862-8867.	7.1	61
42	Extracellular ATP induces the rapid release of HIV-1 from virus containing compartments of human macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3265-73.	7.1	61
43	MCP-1 and CCR2 in HIV infection: regulation of agonist and receptor expression. Journal of Leukocyte Biology, 1997, 62, 30-33.	3.3	60
44	Spreading of HIV-specific CD8+ T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity. Human Immunology, 2001, 62, 561-576.	2.4	55
45	Endogenous CCL2 (monocyte chemotactic protein-1) modulates human immunodeficiency virus type-1 replication and affects cytoskeleton organization in human monocyte-derived macrophages. Blood, 2003, 102, 2334-2337.	1.4	55
46	EXPRESSION OF MONOCYTE CHEMOTACTIC PROTEIN-3 IN HUMAN MONOCYTES EXPOSED TO THE MYCOBACTERIAL CELL WALL COMPONENT LIPOARABINOMANNAN. Cytokine, 1997, 9, 992-998.	3.2	54
47	M1 polarization of human monocyte-derived macrophages restricts pre and postintegration steps of HIV-1 replication. Aids, 2013, 27, 1847-1856.	2.2	54
48	Defective nef Alleles in a Cohort of Hemophiliacs with Progressing and Nonprogressing HIV-1 Infection. Virology, 1999, 259, 349-368.	2.4	53
49	Escape of monocyte-derived dendritic cells of HIV-1 infected individuals from natural killer cell-mediated lysis. Aids, 2003, 17, 2291-2298.	2.2	52
50	Envelope-Dependent Restriction of Human Immunodeficiency Virus Type 1 Spreading in CD4 ⁺ T Lymphocytes: R5 but Not X4 Viruses Replicate in the Absence of T-Cell Receptor Restimulation. Journal of Virology, 1999, 73, 7515-7523.	3.4	52
51	IL-10 Synergizes with Multiple Cytokines in Enhancing HIV Production in Cells of Monocytic Lineage. Journal of Acquired Immune Deficiency Syndromes, 1995, 9, 442-449.	0.3	51
52	Persistent Replication of Severe Acute Respiratory Syndrome Coronavirus in Human Tubular Kidney Cells Selects for Adaptive Mutations in the Membrane Protein. Journal of Virology, 2008, 82, 5137-5144.	3.4	50
53	Human Endometrial Stromal Cells Are Highly Permissive To Productive Infection by Zika Virus. Scientific Reports, 2017, 7, 44286.	3.3	50
54	Efficacy of Low-Dose Intermittent Subcutaneous Interleukin (IL)-2 in Antiviral Drug-Experienced Human Immunodeficiency Virus-Infected Persons with Detectable Virus Load: A Controlled Study of 3 IL-2 Regimens with Antiviral Drug Therapy. Journal of Infectious Diseases, 2001, 183, 1476-1484.	4.0	48

#	ARTICLE	IF	CITATIONS
55	Macrophage Polarization at the Crossroad Between HIV-1 Infection and Cancer Development. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 1145-1152.	2.4	48
56	The Cytokine Network in HIV Infection. <i>Current Molecular Medicine</i> , 2002, 2, 677-689.	1.3	44
57	HTLV-II down-regulates HIV-1 replication in IL-2-stimulated primary PBMC of coinfecting individuals through expression of MIP-1 α . <i>Blood</i> , 2000, 95, 2760-2769.	1.4	43
58	New players in cytokine control of HIV infection. <i>Current HIV/AIDS Reports</i> , 2008, 5, 27-32.	3.1	43
59	A platelet-activating factor antagonist, RP 55778, inhibits cytokine-dependent induction of human immunodeficiency virus expression in chronically infected promonocytic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 2537-2541.	7.1	41
60	Selective inhibition of HIV replication in primary macrophages but not T lymphocytes by macrophage-derived chemokine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 9162-9167.	7.1	41
61	Regulation of HIV expression by viral genes and cytokines. <i>Journal of Leukocyte Biology</i> , 1994, 56, 328-334.	3.3	40
62	Genetic polymorphism of CCR5 gene and HIV disease: The heterozygous (CCR5 Δ 32) genotype is neither essential nor sufficient for protection against disease progression. <i>European Journal of Immunology</i> , 1997, 27, 3223-3227.	2.9	39
63	Inhibition of HIV-1 Replication in Monocyte-Derived Macrophages by <i>Mycobacterium tuberculosis</i> . <i>Journal of Infectious Diseases</i> , 2004, 189, 624-633.	4.0	39
64	Nef Alleles from Human Immunodeficiency Virus Type 1-Infected Long-Term-Nonprogressor Hemophiliacs with or without Late Disease Progression Are Defective in Enhancing Virus Replication and CD4 Down-Regulation. <i>Journal of Virology</i> , 2006, 80, 10663-10674.	3.4	39
65	Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E2284-93.	7.1	39
66	Laureate ESCI award for excellence in clinical science 1999 Cytokines and the human immunodeficiency virus: from bench to bedside. <i>European Journal of Clinical Investigation</i> , 1999, 29, 723-732.	3.4	36
67	The B-Oligomer of Pertussis Toxin Inhibits Human Immunodeficiency Virus Type 1 Replication at Multiple Stages. <i>Journal of Virology</i> , 2000, 74, 8767-8770.	3.4	36
68	Cytokine and Chemokine Based Control of HIV Infection and Replication. <i>Current Pharmaceutical Design</i> , 2001, 7, 993-1013.	1.9	36
69	Naturally occurring C-terminally truncated STAT5 is a negative regulator of HIV-1 expression. <i>Blood</i> , 2007, 109, 5380-5389.	1.4	36
70	Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates. <i>Transfusion Medicine</i> , 2005, 15, 269-276.	1.1	35
71	Postgenomic up-regulation of CCL3L1 expression in HTLV-II-infected persons curtails HIV-1 replication. <i>Blood</i> , 2007, 109, 1850-1856.	1.4	34
72	Cytokines and Soluble Receptor Changes in the Transition from Primary to Early Chronic HIV Type 1 Infection. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 325-331.	1.1	33

#	ARTICLE	IF	CITATIONS
73	The Binding Subunit of Pertussis Toxin Inhibits HIV Replication in Human Macrophages and Virus Expression in Chronically Infected Promonocytic U1 Cells. <i>Journal of Immunology</i> , 2001, 166, 1863-1870.	0.8	33
74	Dissociation between syncytia formation and HIV spreading. Suppression of syncytia formation does not necessarily reflect inhibition of HIV infection. <i>European Journal of Immunology</i> , 1991, 21, 1771-1774.	2.9	31
75	Broad spectrum inhibition of HIV-1 infection by sulfated K5 Escherichia coli polysaccharide derivatives. <i>Aids</i> , 2003, 17, 177-181.	2.2	31
76	Major Histocompatibility Complex Class II Transactivator CIITA Is a Viral Restriction Factor That Targets Human T-Cell Lymphotropic Virus Type 1 Tax-1 Function and Inhibits Viral Replication. <i>Journal of Virology</i> , 2011, 85, 10719-10729.	3.4	31
77	Constitutive Activation of STATs Upon In Vivo Human Immunodeficiency Virus Infection. <i>Blood</i> , 1999, 94, 4202-4209.	1.4	31
78	Single-Nucleotide Polymorphism-Defined Class I and Class III Major Histocompatibility Complex Genetic Subregions Contribute to Natural Long-term Nonprogression in HIV Infection. <i>Journal of Infectious Diseases</i> , 2012, 205, 718-724.	4.0	28
79	1,25-Dihydroxyvitamin D3 Upregulates Functional CXCR4 Human Immunodeficiency Virus Type 1 Coreceptors in U937 Minus Clones: NF- κ B-Independent Enhancement of Viral Replication. <i>Journal of Virology</i> , 1998, 72, 8380-8383.	3.4	27
80	The role of urokinase-type plasminogen activator (uPA)/uPA receptor in HIV-1 infection. <i>Journal of Leukocyte Biology</i> , 2003, 74, 750-756.	3.3	26
81	The interferon-stimulated gene TRIM22 : A double-edged sword in HIV-1 infection. <i>Cytokine and Growth Factor Reviews</i> , 2018, 40, 40-47.	7.2	26
82	Inhibition of Herpes Simplex Virus Types 1 and 2 In Vitro Infection by Sulfated Derivatives of Escherichia coli K5 Polysaccharide. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3078-3084.	3.2	25
83	Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmids and virus-like particles in prime-boost vaccination protocols against SHIV*1. <i>Vaccine</i> , 2003, 21, 2052-2064.	3.8	24
84	Double-edged effect of \hat{V}^39/\hat{V}^2 T lymphocytes on viral expression in an in vitro model of HIV-1/mycobacteria co-infection. <i>European Journal of Immunology</i> , 2003, 33, 252-263.	2.9	23
85	Dendritic Cells and Natural Killer Cells in the Pathogenesis of HIV Infection. <i>Immunologic Research</i> , 2005, 33, 001-022.	2.9	23
86	Pertussis Toxin B-Oligomer Suppresses IL-6 Induced HIV-1 and Chemokine Expression in Chronically Infected U1 Cells via Inhibition of Activator Protein 1. <i>Journal of Immunology</i> , 2006, 176, 999-1006.	0.8	23
87	The Puzzling Role of CXCR4 in Human Immunodeficiency Virus Infection. <i>Theranostics</i> , 2013, 3, 18-25.	10.0	23
88	Reversible Human Immunodeficiency Virus Type-1 Latency in Primary Human Monocyte-Derived Macrophages Induced by Sustained M1 Polarization. <i>Scientific Reports</i> , 2018, 8, 14249.	3.3	23
89	Engagement of CD30 shapes the secretion of cytokines by human $\hat{I}^3 \hat{I}^2$ T cells. <i>European Journal of Immunology</i> , 2000, 30, 2172-2180.	2.9	22
90	Pertussis toxin B-oligomer inhibits HIV infection and replication in hu-PBL-SCID mice. <i>International Immunology</i> , 2005, 17, 469-475.	4.0	22

#	ARTICLE	IF	CITATIONS
91	Extracellular high mobility group box-1 inhibits R5 and X4 HIV-1 strains replication in mononuclear phagocytes without induction of chemokines and cytokines. <i>Aids</i> , 2009, 23, 567-577.	2.2	22
92	Design and Characterization of a Peptide Mimotope of the HIV-1 gp120 Bridging Sheet. <i>International Journal of Molecular Sciences</i> , 2012, 13, 5674-5699.	4.1	22
93	Interleukin-10-induced HIV-1 expression is mediated by induction of both membrane-bound tumour necrosis factor (TNF)- α receptor type 1 in a promonocytic cell line. <i>Aids</i> , 1996, 10, 835-842.	2.2	21
94	Interleukin-6 and Glucocorticoids Synergistically Induce Human Immunodeficiency Virus Type-1 Expression in Chronically Infected U1 Cells by a Long Terminal Repeat Independent Post-Transcriptional Mechanism. <i>Molecular Medicine</i> , 2001, 7, 668-678.	4.4	21
95	Pertussis toxin B-oligomer dissociates T cell activation and HIV replication in CD4 T cells released from infected lymphoid tissue. <i>Aids</i> , 2005, 19, 1007-1014.	2.2	21
96	Activating Killer Immunoglobulin Receptors and HLA-C: a successful combination providing HIV-1 control. <i>Scientific Reports</i> , 2017, 7, 42470.	3.3	21
97	TRIM22. A Multitasking Antiviral Factor. <i>Cells</i> , 2021, 10, 1864.	4.1	21
98	Glucocorticoids Synergize with Tumor Necrosis Factor α in the Induction of HIV Expression from a Chronically Infected Promonocytic Cell Line. <i>AIDS Research and Human Retroviruses</i> , 1993, 9, 547-551.	1.1	20
99	Elevated Levels of Tumor Necrosis Factor- α in Zairian Neonate Plasmas: Implications for Perinatal Infection with the Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 1994, 169, 975-980.	4.0	20
100	Human T-cell leukemia virus type 2 induces survival and proliferation of CD34+ TF-1 cells through activation of STAT1 and STAT5 by secretion of interferon- β and granulocyte macrophage- α colony-stimulating factor. <i>Blood</i> , 2002, 99, 224-231.	1.4	20
101	The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells. <i>Journal of Translational Medicine</i> , 2016, 14, 94.	4.4	20
102	Inhibition of R5X4 Dualtropic HIV-1 Primary Isolates by Single Chemokine Co-receptor Ligands. <i>Virology</i> , 2001, 280, 253-261.	2.4	19
103	Retroviral Interference on STAT Activation in Individuals Coinfected with Human T Cell Leukemia Virus Type 2 and HIV-1. <i>Journal of Immunology</i> , 2002, 169, 4443-4449.	0.8	19
104	The intracellular detection of MIP-1 β enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT. <i>AIDS Research and Therapy</i> , 2008, 5, 22.	1.7	19
105	Impaired CD4+ T-Cell Restoration in the Small Versus Large Intestine of HIV-1- α Positive South Africans Receiving Combination Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2013, 208, 1113-1122.	4.0	19
106	Dendritic cell-specific intercellular adhesion molecule-3 grabbing nonintegrin mediates HIV-1 infection of and transmission by M2a-polarized macrophages in vitro. <i>Aids</i> , 2013, 27, 707-716.	2.2	19
107	TUMOR NECROSIS FACTOR- α DRIVES HIV-1 REPLICATION IN U937 CELL CLONES AND UPREGULATES CXCR4. <i>Cytokine</i> , 2001, 13, 55-59.	3.2	18
108	Novel factors interfering with human immunodeficiency virus-1 replication <i>in vivo</i> and <i>in vitro</i> . <i>Tissue Antigens</i> , 2013, 81, 61-71.	1.0	18

#	ARTICLE	IF	CITATIONS
109	HIV-1 Infected Lymphoid Organs Upregulate Expression and Release of the Cleaved Form of uPAR That Modulates Chemotaxis and Virus Expression. <i>PLoS ONE</i> , 2013, 8, e70606.	2.5	18
110	Engagement of CD30 shapes the secretion of cytokines by human T cells. <i>European Journal of Immunology</i> , 2000, 30, 2172.	2.9	18
111	Ultraviolet irradiation and cytokines as regulators of HIV latency and expression. <i>Chemico-Biological Interactions</i> , 1994, 91, 101-109.	4.0	17
112	Cytokines in the acquired immunodeficiency syndrome and other infectious diseases. <i>International Journal of Clinical and Laboratory Research</i> , 1995, 25, 128-134.	1.0	17
113	Bacterial Toxins: Potential Weapons Against HIV Infection. <i>Current Pharmaceutical Design</i> , 2005, 11, 2909-2926.	1.9	17
114	Negative Regulation of HIV-1 Transcription by a Heterodimeric NF- κ B1/p50 and C-Terminally Truncated STAT5 Complex. <i>Journal of Molecular Biology</i> , 2011, 410, 933-943.	4.2	17
115	Identification of TRIM22 single nucleotide polymorphisms associated with loss of inhibition of HIV-1 transcription and advanced HIV-1 disease. <i>Aids</i> , 2013, 27, 2335-2344.	2.2	17
116	Inhibition of intra- and extra-cellular Tat function and HIV expression by pertussis toxin B-oligomer. <i>European Journal of Immunology</i> , 2004, 34, 530-536.	2.9	16
117	Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesion. <i>Journal of Leukocyte Biology</i> , 2007, 82, 1212-1220.	3.3	16
118	CD14+ macrophages that accumulate in the colon of African AIDS patients express pro-inflammatory cytokines and are responsive to lipopolysaccharide. <i>BMC Infectious Diseases</i> , 2015, 15, 430.	2.9	16
119	Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1. <i>Frontiers in Immunology</i> , 2017, 8, 564.	4.8	16
120	CD30 ligation differentially affects CXCR4-dependent HIV-1 replication and soluble CD30 secretion in non-Hodgkin cell lines and in T lymphocytes. <i>European Journal of Immunology</i> , 2003, 33, 3136-3145.	2.9	15
121	Restoration of anti-tetanus toxoid responses in patients initiating highly active antiretroviral therapy with or without a boost immunization: an INITIO substudy. <i>Clinical and Experimental Immunology</i> , 2008, 152, 252-257.	2.6	15
122	Plastic restriction of HIV-1 replication in human macrophages derived from M1/M2 polarized monocytes. <i>Journal of Leukocyte Biology</i> , 2016, 100, 1147-1153.	3.3	15
123	Immuno-Pharmacological Targeting of Virus-Containing Compartments in HIV-1-Infected Macrophages. <i>Trends in Microbiology</i> , 2016, 24, 558-567.	7.7	15
124	Dual role of TNF- α in NK cell-mediated lysis of chronically HIV-infected U1 cells. Concomitant enhancement of HIV expression and sensitization of cell-mediated lysis. <i>European Journal of Immunology</i> , 1999, 29, 3654-3662.	2.9	14
125	Urokinase Plasminogen Activator Inhibits HIV Virion Release from Macrophage-Differentiated Chronically Infected Cells via Activation of RhoA and PKC μ . <i>PLoS ONE</i> , 2011, 6, e23674.	2.5	14
126	IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes. <i>Journal of Leukocyte Biology</i> , 2002, 72, 735-42.	3.3	14

#	ARTICLE	IF	CITATIONS
127	Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: Possible protective effect of infecting HCV genotype on HIV disease progression. <i>Journal of Clinical Virology</i> , 2007, 39, 82-86.	3.1	13
128	Ligand-engaged urokinase-type plasminogen activator receptor and activation of the CD11b/CD18 integrin inhibit late events of HIV expression in monocytic cells. <i>Blood</i> , 2009, 113, 1699-1709.	1.4	13
129	Asymmetric HIV-1 co-receptor use and replication in CD4+ T lymphocytes. <i>Journal of Translational Medicine</i> , 2010, 9, S8.	4.4	13
130	Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms. <i>Journal of Translational Medicine</i> , 2014, 12, 335.	4.4	13
131	HLA-E restricted CD8+ T Lymphocytes Efficiently Control Mycobacterium tuberculosis and HIV-1 Coinfection. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2020, 62, 430-439.	2.9	13
132	Heterogeneity of Signal Transducer and Activator of Transcription Binding Sites in the Long-Terminal Repeats of Distinct HIV-1 Subtypes. <i>The Open Virology Journal</i> , 2007, 1, 26-32.	1.8	13
133	Transmission of HIV-1 and HCV by head-butting. <i>Lancet, The</i> , 1997, 350, 1370.	13.7	12
134	Interleukin-6 Induces Monocyte Chemotactic Protein-1 in Peripheral Blood Mononuclear Cells and in the U937 Cell Line. <i>Blood</i> , 1998, 91, 258-265.	1.4	12
135	Restricted replication of primary HIV-1 isolates using both CCR5 and CXCR4 in Th2 but not in Th1 CD4(+) T cells. <i>Journal of Leukocyte Biology</i> , 2002, 72, 913-20.	3.3	12
136	The Chronically Infected Promonocytic Cell Line U1: A Model of HIV Expression Regulated by Cytokines. <i>ImmunoMethods</i> , 1993, 3, 50-55.	0.8	11
137	Expression and Activation of a C-Terminal Truncated Isoform of STAT5 (STAT5 ^{tr}) Following Interleukin 2 Administration or AZT Monotherapy in HIV-Infected Individuals. <i>Clinical Immunology</i> , 2001, 99, 75-81.	3.2	11
138	Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy. <i>Blood</i> , 2002, 100, 1575-1578.	1.4	11
139	A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses. <i>Journal of Immunological Methods</i> , 2012, 375, 46-56.	1.4	11
140	CCR2 polymorphism, Syncytium-inducing Human Immunodeficiency Virus Strains, and Disease Progression. <i>Journal of Infectious Diseases</i> , 2000, 182, 1579-1580.	4.0	10
141	INTERLEUKIN (IL)-4 INHIBITS PHORBOL-ESTER INDUCED HIV-1 EXPRESSION IN CHRONICALLY INFECTED U1 CELLS INDEPENDENTLY FROM THE AUTOCRINE EFFECT OF ENDOGENOUS TUMOUR NECROSIS FACTOR- α , IL-1 β , AND IL-1 RECEPTOR ANTAGONIST. <i>Cytokine</i> , 2002, 17, 28-35.	3.2	10
142	Interferon-inducible TRIM22 contributes to maintenance of HIV-1 proviral latency in T cell lines. <i>Virus Research</i> , 2019, 269, 197631.	2.2	10
143	A Community Study of SARS-CoV-2 Detection by RT-PCR in Saliva: A Reliable and Effective Method. <i>Viruses</i> , 2022, 14, 313.	3.3	10
144	Characterization of HIV Type 1 Genetic Diversity Among South African Participants Enrolled in the AIDS Vaccine Integrated Project (AVIP) Study. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 705-709.	1.1	9

#	ARTICLE	IF	CITATIONS
145	The ATP/P2X7 axis in human immunodeficiency virus infection of macrophages. <i>Current Opinion in Pharmacology</i> , 2019, 47, 46-52.	3.5	9
146	Host Restriction Factors Modulating HIV Latency and Replication in Macrophages. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3021.	4.1	9
147	Tumor Necrosis Factor α , Interleukin 2, and Soluble Interleukin 2 Receptor Levels in Human Immunodeficiency Virus Type 1-Infected Individuals Receiving Intermittent Cycles of Interleukin 2. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 491-499.	1.1	8
148	Thymic function and immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia patients. <i>International Journal of Cancer</i> , 2003, 107, 958-961.	5.1	8
149	Nef-specific CD45RA ⁺ CD8 ⁺ T cells secreting MIP-1 β but not IFN- γ are associated with nonprogressive HIV-1 infection. <i>AIDS Research and Therapy</i> , 2010, 7, 20.	1.7	8
150	Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy. <i>Haematologica</i> , 2006, 91, 244-7.	3.5	8
151	Preparing for phase II/III HIV vaccine trials in Africa. <i>Microbes and Infection</i> , 2005, 7, 1436-44.	1.9	7
152	Highlights from the Seventh International Workshop on HIV Persistence during Therapy, 8-11 December 2015, Miami, Florida, USA. <i>Journal of Virus Eradication</i> , 2016, 2, 57-65.	0.5	7
153	Expression and modulation of a mononuclear phagocyte differentiation antigen (PAM-1) during in vitro maturation of peripheral blood monocytes. <i>International Journal of Clinical and Laboratory Research</i> , 1993, 23, 83-87.	1.0	6
154	Role of Peripheral Blood Mononuclear Cell Subsets of Seronegative Donors in HIV Replication: Suppression by CD8 ⁺ and CD16 ⁺ Cells and Enhancement by CD14 ⁺ Monocytes. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 489-491.	1.1	6
155	HIV-1 envelope-dependent restriction of CXCR4-using viruses in child but not adult untransformed CD4 ⁺ T-lymphocyte lines. <i>Blood</i> , 2012, 119, 2013-2023.	1.4	6
156	5-Hydroxytyrosol inhibits HIV-1 replication in primary cells of the lower and upper female reproductive tract. <i>Antiviral Research</i> , 2017, 142, 16-20.	4.1	6
157	Zika Virus: a re-emerging pathogen with rapidly evolving public health implications. <i>New Microbiologica</i> , 2016, 39, 86-90.	0.1	6
158	Three-Year Immune Reconstitution in PI-Sparing and PI-Containing Antiretroviral Regimens in Advanced HIV-1 Disease. <i>Antiviral Therapy</i> , 2007, 12, 553-558.	1.0	6
159	Cytokine Cascades in HIV Infection. , 1996, , 285-301.		5
160	The rise and fall of intermittent interleukin-2 therapy in HIV infection. <i>European Cytokine Network</i> , 2010, 21, 197-201.	2.0	5
161	Defective chemotaxis of human alveolar macrophages. <i>Clinical Immunology and Immunopathology</i> , 1988, 47, 282-288.	2.0	4
162	Ex Vivo Modulation of RANTES and sCD30 by Proinflammatory Stimuli in HIV-Seropositive and -Negative Individuals. <i>Clinical Immunology</i> , 2000, 97, 102-108.	3.2	4

#	ARTICLE	IF	CITATIONS
163	Infection of CD4 + Primary T Cells and Cell Lines, Generation of Chronically Infected Cell Lines, and Induction of HIV Expression. <i>Current Protocols in Immunology</i> , 2005, 69, Unit 12.3.	3.6	4
164	Cell-to-cell vs. cell-free HIV-1 transmission from macrophages to CD4+ T lymphocytes. <i>Aids</i> , 2013, 27, 2307-2308.	2.2	4
165	T lymphocytes of HIV-positive individuals. <i>Aids</i> , 2004, 18, 327-328.	2.2	3
166	Highlights from the Seventh International Workshop on HIV Persistence during Therapy, 8-11 December 2015, Miami, Florida, USA. <i>Journal of Virus Eradication</i> , 2016, 2, 57-65.	0.5	3
167	Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy. <i>Blood</i> , 2002, 100, 1575-8.	1.4	3
168	Unplugging the T cell receptor. <i>Nature Immunology</i> , 2003, 4, 943-944.	14.5	2
169	Unsung Hero Robert C. Gallo. <i>Science</i> , 2009, 323, 206-207.	12.6	2
170	Post-entry events of efficient R5 vs. inefficient X4 HIV-1 replication in primary CD4+T lymphocytes, a transcriptome analysis. <i>Retrovirology</i> , 2009, 6, 119.	2.0	2
171	Introducing the issue on "Differential use of CCR5 versus CXCR4 by HIV-1. Pathogenic, Translational and Clinical Open Questions" <i>Journal of Translational Medicine</i> , 2011, 9, 11.	4.4	2
172	Passport control for foreign integrated DNAs. <i>Mobile Genetic Elements</i> , 2012, 2, 233-238.	1.8	2
173	Immunopathogenesis of HIV Infection. , 2007, , 245-295.		2
174	Infection of CD 4 + Primary Cell Lines and Induction of HIV. <i>Current Protocols in Immunology</i> , 1993, 5, 12.3.1.	3.6	1
175	Multiple Roles of Cytokines in HIV Infection, Replication, and Therapy. , 0, , 293-311.		1
176	Improved thymopoietic potential in aviremic HIV infected individuals treated with HAART by intermittent IL-2 administration. <i>Aids</i> , 2003, 17, 1621-1630.	2.2	1
177	Persistence of CCR5 usage among primary human immunodeficiency virus isolates of individuals receiving intermittent interleukin-2. <i>HIV Medicine</i> , 2010, 11, 349-352.	2.2	1
178	Old and new plasma biomarkers in HIV-1-infected African-American women. <i>Aids</i> , 2011, 25, 1921-1923.	2.2	1
179	Strenuous resistance to natural HIV-1 disease progression: viral controllers and long-term nonprogressors. <i>Future Virology</i> , 2011, 6, 521-533.	1.8	1
180	Chronically infected T-cell lines become handy for a novel assay measuring the reservoir of replication-competent HIV-1. <i>Aids</i> , 2017, 31, 2555-2556.	2.2	1

#	ARTICLE	IF	CITATIONS
181	P-D2 TRIM22 binds to CIITA and sequesters it into nuclear bodies containing TRIM19/PML and Cyclin T1: Implications for HIV-1 infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 59-59.	2.1	1
182	D-105 Reversible HIV-1 Latency Induced in Primary Human Monocyte-Derived Macrophages by Repeated M1 Polarization. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 40-40.	2.1	1
183	Dual role of TNF- α in NK α /LAK cell-mediated lysis of chronically HIV-infected U1 cells. Concomitant enhancement of HIV expression and sensitization of cell-mediated lysis. <i>European Journal of Immunology</i> , 1999, 29, 3654-3662.	2.9	1
184	Double doors and gatekeepers: HIV co-receptors and chemokines. <i>Drug News and Perspectives</i> , 1998, 11, 620.	1.5	1
185	Glycosyl Phosphatidylinositol-Anchored Proteins and HIV Infection. <i>Letters in Drug Design and Discovery</i> , 2006, 3, 598-604.	0.7	1
186	Highlights from the 8 International Workshop on HIV Persistence during Therapy, 12-15 December 2017, Miami, FL, USA. <i>Journal of Virus Eradication</i> , 2018, 4, 132-142.	0.5	1
187	Jurkat-Derived (J-Lat, J1.1, and Jurkat E4) and CEM-Derived T Cell Lines (8E5 and ACH-2) as Models of Reversible Proviral Latency. <i>Methods in Molecular Biology</i> , 2022, 2407, 3-15.	0.9	1
188	U1 and OM10.1. Myeloid Cell Lines as Surrogate Models of Reversible Proviral Latency. <i>Methods in Molecular Biology</i> , 2022, 2407, 17-28.	0.9	1
189	Nitric Oxide Production in HIV-1 Infected Patients Receiving Intermittent Cycles of Interleukin-2 and Antiretrovirals. <i>HIV Clinical Trials</i> , 2004, 5, 146-151.	2.0	0
190	Immunomodulatory and Anti-Viral Activities of Pertussis Toxin and of Its Non-Toxic Derivatives. <i>Current Medicinal Chemistry Anti-inflammatory & Anti-allergy Agents</i> , 2005, 4, 177-183.	0.4	0
191	Busting a gut understanding HIV pathogenesis in lymphoid tissue. <i>Future HIV Therapy</i> , 2007, 1, 247-250.	0.4	0
192	Naturally C-Terminally truncated STAT5 (STAT5 Δ): a novel negative controller of HIV-1 transcription and expression. <i>Retrovirology</i> , 2009, 6, .	2.0	0
193	681. HIV-1 Mediated Insertional Activation of STAT5B and BACH2 Promotes the Formation of a Viral Reservoir in T Regulatory Cells. <i>Molecular Therapy</i> , 2016, 24, S269-S270.	8.2	0
194	Highlights from the 8th International Workshop on HIV Persistence during Therapy, 12-15 December 2017, Miami, FL, USA. <i>Journal of Virus Eradication</i> , 2018, 4, 132-142.	0.5	0
195	HIV Latency and Reactivation: The Early Years. , 2008, , 279-287.		0
196	HIV and Cytokines. , 2011, , 139-153.		0
197	Highlights of the 9th edition of the Conference on HIV Persistence During Therapy, 10-13 December 2019, Miami, USA. <i>Journal of Virus Eradication</i> , 2020, 6, 85-95.	0.5	0
198	Human Monocyte-Derived Macrophages (MDM): Model 2. <i>Methods in Molecular Biology</i> , 2022, 2407, 97-101.	0.9	0